Overview: EGFR ctDNA Liquid Biopsy TestIntroduction: The EGFR ctDNA Liquid Biopsy Test detects EGFR mutations in circulating tumor DNA to diagnose lung cancer, causing cough or pain. Aligned with 2023 NCCN guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected non-small cell lung cancer.
Other Names: EGFR ctDNA Assay, Lung Cancer Liquid Biopsy.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: EGFR ctDNA testing emerged in the 2010s with liquid biopsy research. PCR methods improved in the 2020s, enhancing diagnostic precision.
Purpose: Detects EGFR mutations in ctDNA to diagnose lung cancer, guides treatment, and evaluates patients with cough or pain.
Test Parameters: 1. EGFR ctDNA
Pretest Condition: No fasting required. Collect plasma or serum. Report history of cough, pain, or lung cancer symptoms.
Specimen: Plasma (EDTA, 2-4 mL), Serum (SST, 2-5 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document cough, pain, weight loss, or family history of lung cancer. Include current medications, especially targeted therapies.
Consent: Written consent required, detailing the tests purpose, lung cancer implications, and risks of blood collection.
Procedural Considerations: Uses PCR to detect EGFR mutations in ctDNA from plasma or serum. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for targeted therapy eligibility.
Factors Affecting Result Accuracy: Low ctDNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive EGFR mutations confirm lung cancer, guiding anti-EGFR therapy (e.g., osimertinib). Negative results may require tissue biopsy.
Specialist Consultation: Consult an oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Tissue-based EGFR testing, ALK mutation testing, or PET-CT to confirm lung cancer diagnosis.
Test Limitations: Sensitivity depends on ctDNA levels; clinical correlation is needed. Not all EGFR mutations are detected.
References: NCCN Lung Cancer Guidelines, 2023; Journal of Clinical Oncology, Reck M, 2022.
